logo
Measles 'out of control,' experts warn, as Alberta case counts surpass 1,000

Measles 'out of control,' experts warn, as Alberta case counts surpass 1,000

Yahoo11 hours ago

Alberta's measles outbreaks have now eclipsed the 1,000-case mark and infectious disease specialists are warning the virus is "impossible to contain," given the current level of transmission.
The province reported another 24 cases on Friday, including 14 in the north zone, nine in the south and one in the Edmonton zone.
This brings the total confirmed cases since the outbreaks began in March to 1,020.
"It is a very grim milestone," said Dr. Karina Top, a pediatric infectious disease physician at the Stollery Children's Hospital in Edmonton, which has been treating children with measles.
"I'm very worried we're going to see more hospitalizations and some deaths soon because we know the death rate is about one to two per thousand. So it's likely that we're going to see that and that will be a very tragic day."
Measles is highly contagious and can lead to serious complications including pneumonia, brain inflammation — which can trigger seizures, deafness and brain damage — as well as premature delivery.
A premature baby who was born with measles died in Ontario recently. And another young child died of measles in that province last year.
Doctors warn there are severe long-term consequences as well, including immune system impacts and a degenerative neurological condition that occurs seven to ten years after an initial measles infection. It is rare but nearly always fatal.
'Out of control'
Alberta's case count has more than doubled in the last month. On May 20, a total of 486 cases had been confirmed.
"This is out of control," said Top.
The hardest hit areas are the south, central and north zones, where there are some very low vaccination rates among young children.
Case counts have been rising quickly in the north zone, which has now topped 200 cases. The south zone has confirmed 681 cases and the central zone has 105.
And health officials are warning the virus is more widespread in those areas than case counts reflect.
"Due to the number of people in these areas who may not be immune to measles, it's likely that some cases are going undetected or unreported," the Alberta government's measles web page states.
"I think we really need to be doing everything we can to engage with those communities that are affected and community leaders to see how best we can work with them to try to get people vaccinated to help contain this infection," said Top.
"And [we need to] get everyone else up to date so that if there are other cases introduced in Edmonton, Calgary or elsewhere in the province, it can be contained more quickly."
University of Calgary infectious disease physician Dr. Dan Gregson is also worried about Alberta's surging measles cases.
"This transmission is just out of the box. It's impossible to contain at the present time," he said.
"The risk, right now, of your child getting measles in Alberta if they're not immunized is pretty high."
Gregson is urging parents who have opted not to immunize their children to rethink that decision.
"If you had made a decision not to vaccinate because measles was not circulating, that's no longer true. We don't have herd immunity. There's measles circulating in the community. And the best way to prevent your child from having a complication would be to get them vaccinated," he said.
The vast majority of Alberta's measles cases are among the unimmunized.
The most recent data shows 85 Albertans have been hospitalized due to this year's outbreaks, including 14 who have ended up in intensive care.
"Most of these hospitalizations are due to patients having pneumonia — they're short of breath, they have to wear oxygen. Some of them are due to brain inflammation. [It's] not a pleasant thing for the parents or the child to have to go through," said Gregson.
In Edmonton, where the Stollery Children's Hospital is treating the sickest patients from northern Alberta, Top said the outbreaks are taking a toll.
"It is distressing as a pediatrician to see children that are sick from a disease that is completely vaccine preventable."
According to provincial data, as of Friday there was one Albertan in ICU due to measles. No deaths have been reported.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

Yahoo

time2 hours ago

  • Yahoo

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why
Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why

Yahoo

time2 hours ago

  • Yahoo

Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why

Oscar Health, Inc. (NYSE:OSCR) is one of the Oscar Health extended its winning streak to a fourth consecutive day on Friday, jumping 13.05 percent to close at $21.22 apiece as investor sentiment was influenced by the previous days' surge. During the shortened, four-day trading week, shares of Oscar Health, Inc. (NYSE:OSCR) already grew by 52 percent, with analysts pointing to meme trading as having buoyed its share prices. Additionally, investor sentiment was supported by a new proposal for Medicare that would allow individuals and employers to enroll in a new version called 'Part E.' A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. While this would heighten competition with private insurers such as Oscar Health, Inc. (NYSE:OSCR), the voluntary enrollment could potentially delay or prevent Medicare's sooner-than-expected insolvency. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why
Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why

Yahoo

time2 hours ago

  • Yahoo

Oscar Health (OSCR) Soars 13% on Fourth Straight Day, Here's Why

Oscar Health, Inc. (NYSE:OSCR) is one of the Oscar Health extended its winning streak to a fourth consecutive day on Friday, jumping 13.05 percent to close at $21.22 apiece as investor sentiment was influenced by the previous days' surge. During the shortened, four-day trading week, shares of Oscar Health, Inc. (NYSE:OSCR) already grew by 52 percent, with analysts pointing to meme trading as having buoyed its share prices. Additionally, investor sentiment was supported by a new proposal for Medicare that would allow individuals and employers to enroll in a new version called 'Part E.' A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. While this would heighten competition with private insurers such as Oscar Health, Inc. (NYSE:OSCR), the voluntary enrollment could potentially delay or prevent Medicare's sooner-than-expected insolvency. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store